Fundz

Dova Pharmaceuticals, Inc. reported raising $10 Million in an initial SEC Form D filing, from an offering of $40 Million

PRIVATESep 23, 2016$10M of $40M raised

Amount Raised

$10 Million

$10 Million sold, per SEC Form D (first sale Sep 23, 2016)

Round Type

Venture

CharlottesvilleHealthcare

Quick answer

Dova Pharmaceuticals, Inc. raised $10 Million in a funding round, dated September 23, 2016. Dova Pharmaceuticals, Inc. is based in Charlottesville, Virginia, United States.

How much did Dova Pharmaceuticals, Inc. raise?
Dova Pharmaceuticals, Inc. raised $10 Million in a funding round on September 23, 2016.
What does Dova Pharmaceuticals, Inc. do?
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need.
Where is Dova Pharmaceuticals, Inc. based and how big is it?
Dova Pharmaceuticals, Inc. is based in Charlottesville, Virginia, United States.

Source: Fundz verified event record.

Who else raised in Healthcare around the same time

Companies in the same sectors as Dova Pharmaceuticals, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • ActX raised $1.9M (Seed) on November 7, 2016.
  • INFACARE PHARMACEUTICAL CORP raised $5.5M on November 4, 2016.
  • Emerald TopCo, Inc. raised $1.3B on November 4, 2016.
  • Skye Bioscience raised $500K (Seed) on November 4, 2016.
  • Crispr Therapeutics raised $35M on November 4, 2016.
  • UVLrx Therapeutics, Inc. raised $206K (Pre-Seed) on November 4, 2016.

Who to call at Dova Pharmaceuticals, Inc., and when

A new round usually means Dova Pharmaceuticals, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Dova Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Dova Pharmaceuticals, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Dova Pharmaceuticals, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Dova Pharmaceuticals, Inc.

Location

200 GARRETT STREET

Charlottesville, Virginia, United States

About

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Dova Pharmaceuticals, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Dova Pharmaceuticals, Inc.'s next move

See what Strategic adds

Dova Pharmaceuticals, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.